Table 2.
RNA-based therapies in large animal models of cell-free cardiac regeneration.
| RNA-Based Therapies | ||||
|---|---|---|---|---|
| Molecule (Delivery Method) | Animal Model Sample Size Follow-Up |
Main Effects | Proposed Mechanism | |
| miR-199a AAV6 mc. |
Pig (AMI) (n = 19) 8 w |
↑ LVEF (+17.1%) ↓ Scar size/mass (−50%) ↓ Fibrosis |
CM cell-cycle reentry | [42] |
| antimiR-132 i.c./i.v. |
Pig (AMI) (n = 156) 56 d |
↑ LVEF ↓ Scar size ↓ Fibrosis ↓ CM size |
↑ Foxo3 (anti-fibrotic)↑ Serca2a |
[48] |
| antagomiR-92a i.v./i.c. |
Pig (AMI) (n = 30) 7 d |
↑ LVEF ↑ Capillary density |
↑ Angiogenesis ↓ Inflammation ↓ CM apoptosis |
[50] |
| PLGA antagomir-92a i.c. |
Pig (AMI) (n = 27) 10 d |
↑ LVEF ↓ Adverse remodeling |
[51] | |
Main effects are always reported as (control vs. treatment), if no second value is reported, the value is the calculated relative difference between control and treatment. Only significant values are reported in the main effects column (p < 0.05). Sample size reports the total number of animals enrolled in the study. Abbreviations: CM: cardiomyocyte.